This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krajden, M.
Right arrow Articles by Comanor, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krajden, M.
Right arrow Articles by Comanor, L.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, September 2004, p. 4054-4059, Vol. 42, No. 9
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.9.4054-4059.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Evaluation of the Core Antigen Assay as a Second-Line Supplemental Test for Diagnosis of Active Hepatitis C Virus Infection

Mel Krajden,1* Rishma Shivji,1 Kingsley Gunadasa,1 Annie Mak,1 Gail McNabb,1 Michel Friesenhahn,2 David Hendricks,2 and Lorraine Comanor3

British Columbia Center for Disease Control, Vancouver, British Columbia, Canada,1 Bayer Healthcare LLC, Berkeley, California,2 Independent Research Consultant, Palo Alto, California3

Received 24 February 2004/ Returned for modification 12 April 2004/ Accepted 9 May 2004

The British Columbia Center for Disease Control laboratory performs approximately 95% of all hepatitis C virus (HCV) antibody tests for the province's 4 million inhabitants. In 2002, the laboratory tested 96,000 specimens for anti-HCV antibodies, of which 4,800 (5%) were seroreactive and required confirmation of active infection. Although HCV RNA assays with a sensitivity of 50 IU/ml or less are recommended for the confirmation of active HCV infection, given the large number of seroreactive specimens tested annually, we evaluated the Ortho trak-C assay (OTCA) as a second-line confirmatory test and determined its limit of detection (LoD). Of 502 specimens from treatment-naïve anti-HCV-positive individuals, 478 had sufficient volumes for evaluation by the OTCA and HCV RNA tests. Core antigen was not detected in 147 of 478 (30.8%) of these specimens, of which 37 of 147 (25.2%) were shown to be viremic by the VERSANT HCV (version 3.0) (branched-DNA) assay and/or the VERSANT HCV qualitative assay. Testing of 144 replicates of a World Health Organization standard dilution series indicated that the LoD of OTCA was ~27,000 IU/ml. This LoD is consistent with the inability of OTCA to detect core antigen in clinical specimens with low viral loads. We conclude that OTCA has limited value as a confirmatory test for the diagnosis of active HCV infection because 37 of 367 (10%) of viremic specimens had undetectable core antigen. Qualitative HCV RNA testing remains the present standard for the confirmation of active HCV infection in the diagnostic setting.


* Corresponding author. Mailing address: British Columbia Center for Disease Control, 655 W. 12th Ave., Vancouver, BC V5Z4R4, Canada. Phone: (604) 660-6044. Fax: (604) 660-6073. E-mail: mel.krajden{at}bccdc.ca.


Journal of Clinical Microbiology, September 2004, p. 4054-4059, Vol. 42, No. 9
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.9.4054-4059.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Schnuriger, A., Dominguez, S., Valantin, M.-A., Tubiana, R., Duvivier, C., Ghosn, J., Simon, A., Katlama, C., Thibault, V. (2006). Early Detection of Hepatitis C Virus Infection by Use of a New Combined Antigen-Antibody Detection Assay: Potential Use for High-Risk Individuals. J. Clin. Microbiol. 44: 1561-1563 [Abstract] [Full Text]  
  • Laperche, S., Le Marrec, N., Girault, A., Bouchardeau, F., Servant-Delmas, A., Maniez-Montreuil, M., Gallian, P., Levayer, T., Morel, P., Simon, N. (2005). Simultaneous Detection of Hepatitis C Virus (HCV) Core Antigen and Anti-HCV Antibodies Improves the Early Detection of HCV Infection. J. Clin. Microbiol. 43: 3877-3883 [Abstract] [Full Text]